Logo image of BIAF

BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Price, Quote, News and Overview

NASDAQ:BIAF - Nasdaq - US09076W1099 - Common Stock - Currency: USD

0.343  -0.02 (-6.03%)

After market: 0.3503 +0.01 (+2.13%)

BIAF Quote, Performance and Key Statistics

BIOAFFINITY TECHNOLOGIES INC

NASDAQ:BIAF (7/22/2025, 8:00:01 PM)

After market: 0.3503 +0.01 (+2.13%)

0.343

-0.02 (-6.03%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.75
52 Week Low0.16
Market Cap9.76M
Shares28.46M
Float23.05M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO08-26 2022-08-26


BIAF short term performance overview.The bars show the price performance of BIAF in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40

BIAF long term performance overview.The bars show the price performance of BIAF in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BIAF is 0.343 USD. In the past month the price increased by 49.13%. In the past year, price decreased by -87.34%.

BIOAFFINITY TECHNOLOGIES INC / BIAF Daily stock chart

BIAF Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.22 330.51B
AMGN AMGEN INC 14.72 164.37B
GILD GILEAD SCIENCES INC 14.23 137.04B
VRTX VERTEX PHARMACEUTICALS INC N/A 120.73B
REGN REGENERON PHARMACEUTICALS 12.66 60.56B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 42.41B
ARGX ARGENX SE - ADR 99.34 34.88B
ONC BEONE MEDICINES LTD-ADR 7.56 31.99B
BNTX BIONTECH SE-ADR N/A 26.79B
SMMT SUMMIT THERAPEUTICS INC N/A 19.71B
INSM INSMED INC N/A 19.52B
NTRA NATERA INC N/A 19.11B

About BIAF

Company Profile

BIAF logo image bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

Company Info

BIOAFFINITY TECHNOLOGIES INC

3300 Nacogdoches Road, Suite 216

San Antonio TEXAS US

Employees: 14

BIAF Company Website

BIAF Investor Relations

Phone: 12106985334

BIOAFFINITY TECHNOLOGIES INC / BIAF FAQ

What is the stock price of BIOAFFINITY TECHNOLOGIES INC today?

The current stock price of BIAF is 0.343 USD. The price decreased by -6.03% in the last trading session.


What is the ticker symbol for BIOAFFINITY TECHNOLOGIES INC stock?

The exchange symbol of BIOAFFINITY TECHNOLOGIES INC is BIAF and it is listed on the Nasdaq exchange.


On which exchange is BIAF stock listed?

BIAF stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BIOAFFINITY TECHNOLOGIES INC stock?

6 analysts have analysed BIAF and the average price target is 6.12 USD. This implies a price increase of 1684.26% is expected in the next year compared to the current price of 0.343. Check the BIOAFFINITY TECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIOAFFINITY TECHNOLOGIES INC worth?

BIOAFFINITY TECHNOLOGIES INC (BIAF) has a market capitalization of 9.76M USD. This makes BIAF a Nano Cap stock.


How many employees does BIOAFFINITY TECHNOLOGIES INC have?

BIOAFFINITY TECHNOLOGIES INC (BIAF) currently has 14 employees.


What are the support and resistance levels for BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?

BIOAFFINITY TECHNOLOGIES INC (BIAF) has a support level at 0.33 and a resistance level at 0.36. Check the full technical report for a detailed analysis of BIAF support and resistance levels.


Is BIOAFFINITY TECHNOLOGIES INC (BIAF) expected to grow?

The Revenue of BIOAFFINITY TECHNOLOGIES INC (BIAF) is expected to decline by -32.09% in the next year. Check the estimates tab for more information on the BIAF EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOAFFINITY TECHNOLOGIES INC (BIAF) stock pay dividends?

BIAF does not pay a dividend.


When does BIOAFFINITY TECHNOLOGIES INC (BIAF) report earnings?

BIOAFFINITY TECHNOLOGIES INC (BIAF) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of BIOAFFINITY TECHNOLOGIES INC (BIAF)?

BIOAFFINITY TECHNOLOGIES INC (BIAF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).


What is the Short Interest ratio of BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?

The outstanding short interest for BIOAFFINITY TECHNOLOGIES INC (BIAF) is 19.06% of its float. Check the ownership tab for more information on the BIAF short interest.


BIAF Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to BIAF. When comparing the yearly performance of all stocks, BIAF is a bad performer in the overall market: 98.37% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BIAF Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to BIAF. Both the profitability and financial health of BIAF have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIAF Financial Highlights

Over the last trailing twelve months BIAF reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS increased by 22.05% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -175.55%
ROE -676.56%
Debt/Equity 0.27
Chartmill High Growth Momentum
EPS Q2Q%17.33%
Sales Q2Q%-22.97%
EPS 1Y (TTM)22.05%
Revenue 1Y (TTM)78.33%

BIAF Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to BIAF. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of 51.22% and a revenue growth -32.09% for BIAF


Ownership
Inst Owners1.75%
Ins Owners16.79%
Short Float %19.06%
Short Ratio0.51
Analysts
Analysts43.33
Price Target6.12 (1684.26%)
EPS Next Y51.22%
Revenue Next Year-32.09%